Galectin Therapeutics (GALT) Proxy filing summary

Executive summary

• Annual meeting scheduled for Dec. 3, 2026, at 11:00 a.m. EST, virtually; voting deadline is Dec. 2, 2026, at 11:59 p.m. ET.

Voting matters and shareholder proposals

• Shareholders will vote on 11 director nominees, an increase in authorized common shares, an equity plan share reserve increase, and auditor ratification; the board recommends For each proposal.

• Proposal 3 seeks approval to add 3,000,000 shares to the 2019 Omnibus Equity Incentive Plan reserve.

Board of directors and corporate governance

• Eleven director nominees: Gilbert F. Amelio, Henry Brem, Benjamin S. Carson Sr., Kary Eldred, Kevin D. Freeman, Joel Lewis, Gilbert S. Omenn, Elissa J. Schwartz, Harold H. Shlevin, Richard E. Uihlein, and Richard A. Zordani.